Navigation Links
Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells
Date:5/31/2014

At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open for OMP-54F28 (FZD8-Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, being offered at the CU Cancer Center and elsewhere.

"These are optimistic results for one of the first targeted therapies for cancer stem cells," says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell-Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer Center site. "And it is great to work with such a science-focused sponsor, whose vision aligns with ours: bringing to the clinic cutting-edge drugs and ideas that are focused on targeting CSCs. In the context of the collaboration between the Gates Center for Stem Cell Biology and the CU Cancer Center this was the second clinical trial we offered to our patients with the specific intent to eliminate the CSCs in their tumors."

OMP-54F28 (FZD8-Fc) is an antagonist of the Wnt pathway, a key CSC signaling pathway that regulates the fate of these cells. The Wnt pathway is known to be inappropriately activated in many major tumor types, including colon, breast, liver, lung and pancreatic cancers, and is critical for the function of CSCs. Because of this extensive validation, in the Jimeno lab and elsewhere, the Wnt pathway has been a major focus of anti-cancer drug discovery efforts. OMP-54F28 (FZD8-Fc) and a sister compound also developed by OncoMed, vantictumab (OMP-18R5), are two of the first therapeutic agents targeting t
'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. ChromaDex® Announces Financial Results for the Year Ended 2011
2. Aware, Inc. Reports First Quarter 2012 Financial Results
3. Better housing conditions for zebrafish could improve research results
4. NIH-led study finds genetic test results do not trigger increased use of health services
5. New Tool Helps Drug Developers Optimize Their Research and Target Development for Better Results and a Stronger Competitive Edge
6. Study results: Adult stem cells from bone marrow
7. SF State researcher releases first results from nationwide bee count
8. Aware, Inc. Reports Second Quarter 2012 Financial Results
9. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
10. Aware, Inc. Reports Third Quarter 2012 Financial Results
11. Consumers have few negative reactions to the results of genetic testing for cancer mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... published in the September 2013 issue of the ... Psychiatry found that young adults with an autism ... than their peers with different disabilities. Using data ... longitudinal nationally-representative survey of youth ages 13-16 years as ...
... of Michigan researchers today released seven technical reports ... on hydraulic fracturing, the controversial natural gas and ... The studies, totaling nearly 200 pages, examine seven ... fracturing in Michigan, with an emphasis on high-volume ...
... BGI in collaboration with Institute of Biophysics, Chinese Academy ... genome sequencing of 161 Mycobacterium tuberculosis that ... published online in Nature Genetics provides an ... basis underlying drug resistance TB. TB is one ...
Cached Biology News:Young adults with autism found to have difficulty transitioning into employment 2U-M technical reports examine hydraulic fracturing in Michigan 2U-M technical reports examine hydraulic fracturing in Michigan 3U-M technical reports examine hydraulic fracturing in Michigan 4U-M technical reports examine hydraulic fracturing in Michigan 5U-M technical reports examine hydraulic fracturing in Michigan 6U-M technical reports examine hydraulic fracturing in Michigan 7Drug resistance-associated genes: A cornerstone for the control and protection against tuberculosis 2
(Date:5/4/2015)... , May 4, 2015   Tocagen ... updated interim data from Tocagen,s ongoing investigational studies ... Symposium of the American Association of Neurological Surgeons ... held May 1-2, 2015, in Washington, ... company held a meeting with FDA and continues ...
(Date:5/1/2015)... May 1, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced today ... second tranche of a $40 million investment from Woodford ... first invested $25 million in NW Bio on November ... an agreement with the Company for a further $40 ...
(Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North American ... is the proud recipient of two Cisco® Partner Summit Country ... of the Year and Security Partner of the Year for ... taking place this week in Montreal . ... but two Cisco partner awards at this year,s conference," said ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4
... July 13 Measuring the change in circulating tumor ... survival in patients with metastatic breast cancer (MBC), according ... issue of the Journal of Clinical ... and a more sensitive than conventional modality, fluorodeoxyglucose positron ...
... SAN MARINO, Calif., July 13 Viral Genetics (Pink ... autoimmune diseases, and cancer, has retired the majority of its $3.5 ... recently issued new shares. , , ... issuance of shares. This transaction originally was disclosed March 29, 2006, ...
... method that can estimate the origin and time of ... detection of the first few cases has been developed ... for Outbreak Analysis and Modelling at Imperial College London ... Assessment group. The method, described in an ...
Cached Biology Technology:Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer 2Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer 3Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer 4Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances 2Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances 3Novel method predicts impact of a covert anthrax release 2
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Biology Products: